Thank you very much, Mr. Chair.
Thank you to the witnesses for appearing before us today.
Dr. Saunders or Mr. Tierney, you've heard the criticisms of CDR. Some people will claim it's a barrier to patient access to new drugs; that it's an exercise in cost containment, and not what is best for patient health; that there's a lack of accountability and transparency. I'd like to ask whichever one of you wants to respond, and I've relatively short questions. If you could give me relatively short answers, that would be wonderful, because I only have five minutes.
Wouldn't open door meetings increase the transparency of the CDR, and what would be the disadvantages of having open door meetings?